Selected U.S. Products

Cimzia^®

Cimzia^® (certolizumab pegol) is indicated in the U.S. for treatment of adults with moderately to severely active rheumatoid arthritis.

Cimzia^® (certolizumab pegol) is indicated in the U.S. for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
Consult www.cimzia.com for full prescribing information.

Vimpat^®

Vimpat® (lacosamide) C-Ⅴ tablets are indicated for adjunctive therapy in the treatment of partial-onset seizures in patients 17 years of age and older. Vimpat® injection is indicated as short-term replacement when oral administration is not feasible in these patients. (Consult www.vimpat.com for full prescribing information.)

Keppra XR™

Keppra XR™ (levetiracetam) extended-release tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in patients 16 years of age and older with epilepsy.
Consult www.keppraXR.com for full prescribing information.

Consult www.keppra.com for Keppra^® (levetiracetam) tablets, oral solution and injection full prescribing information.

Metadate CD^®

Metadate CD^® (methylphenidate HCl, USP) Extended Release capsules, CII are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Click here for full prescribing information.

Tussionex^® Pennkinetic^®

Tussionex^® Pennkinetic^® (hydrocodone polistirex and chlorpheniramine polistirex) Extended-Release Suspension, CIII is indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older.
Consult www.tussionex.com for full prescribing information.

Cimzia^®, Keppra XR^TM, Metadate CD^® and Tussionex^® Pennkinetic^® are trademarks of the UCB Group of Companies.

Vimpat® is a registered trademark under license from Harris FRC Corporation.